PMID: 8426016Feb 1, 1993

Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion

Journal of the American College of Cardiology
P GolinoM Chiariello

Abstract

The aim of this study was to assess whether prostaglandin endoperoxides, which continue to be formed in the setting of thromboxane A2 synthase inhibition, might influence the fate of ischemic myocardium in a model of coronary occlusion and reperfusion. It was recently demonstrated that thromboxane A2 synthase inhibitors reduce ischemic myocardial injury through a redirection of prostaglandin (PG) endoperoxides toward the synthesis of "cardioprotective" prostaglandins, such as PGI2, PGE2 and PGD2. However, part of these prostaglandin endoperoxides may also stimulate a receptor, shared with thromboxane A2, mediating platelet aggregation and vasoconstriction. New Zealand White rabbits were subjected to 30 min of coronary occlusion, followed by 5.5 h of reperfusion. Fifteen minutes before reperfusion, the animals were randomized to receive 1) saline solution (control animals, n = 8); 2) SQ 29548, a potent and selective thromboxane A2/PGH2 receptor antagonist (n = 8); 3) dazoxiben, a selective thromboxane A2 synthase inhibitor (n = 8); 4) R 68070 (Ridogrel), a drug with dual thromboxane A2 synthase-inhibiting and thromboxane A2/PGH2 receptor-blocking properties (n = 8); or 5) aspirin + R 68070 (n = 8). Dazoxiben and R 68070, but not...Continue Reading

References

Apr 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·P NeedlemanM Minkes
Apr 1, 1977·Prostaglandins·S MoncadaP Needleman
Jun 1, 1990·Journal of the American College of Cardiology·Y ShiS Goldberg
Jan 1, 1988·Journal of Cardiovascular Pharmacology·G J Grover, W A Schumacher
Nov 1, 1988·The Journal of Clinical Investigation·D J FitzgeraldG A FitzGerald
Dec 1, 1974·The Journal of Clinical Investigation·R A KlonerR B Jennings
Feb 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Sep 1, 1983·Journal of Cardiovascular Pharmacology·S E BurkeA M Lefer
Aug 1, 1983·Journal of the American College of Cardiology·J A Melin, L C Becker
Mar 1, 1983·Biochemical Pharmacology·F De Clerck, J M Van Nueten
Oct 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·L W DeBoerE Braunwald
Apr 1, 1981·The American Journal of Cardiology·R BolliS E Epstein
Mar 1, 1980·Canadian Journal of Physiology and Pharmacology·E F SmithJ B Smith
Feb 1, 1981·The American Journal of Cardiology·R O BonowS E Epstein

Citations

May 1, 1994·Agents and Actions·S D SethS K Maulik
Aug 1, 1996·Pflügers Archiv : European journal of physiology·J A BarrabésJ Soler-Soler
Apr 18, 2002·British Journal of Pharmacology·Cherry L WainwrightPiero Del Soldato
Oct 1, 1995·Chest·J I WeitzP Théroux
Nov 20, 1998·Chest·J I Weitz, J Hirsh
Feb 27, 2003·Journal of Cardiovascular Pharmacology·Zhi-Dong GeG J Gross
Jun 13, 2000·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·P GolinoM Chiariello
Apr 25, 2000·American Journal of Physiology. Heart and Circulatory Physiology·P GolinoM Chiariello

Related Concepts

UK 37248-01
7-(3-((2-((phenylamino)carbonyl)hydrazino)methyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid
R 70416
Metazoa
Micristin
Hydrazines
Imidazoles
Myocardial Infarction
Pentanoic Acids
Platelet Aggregation

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.